soul trial oral semaglutide cardiovascular outcomes 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM ACC 2025: Oral Semaglutide Reduces

Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout

Figure 2 shows that the biphasic PK profile obtained from the two-compartment model is consistent with intravenous data and, furthermore, that the rate of absorption as well as the maximum concentration following subcutaneous doses of different strengths were well captured by the model

The staff is amazing as well

InjectaMax is a multi-mineral injection for cattle that contains copper, manganese, zinc, selenium and vitamin B12

11, 23 Conversely, a minority of sporadic medullary thyroid carcinomas, namely 2/10 (20%), did express a measurable amount of GLP1R by immunohistochemistry in our study

Access to generic compounded GLP-1 medications (semaglutide) , which are not FDA-approved but are produced by USP-compliant, state-regulated pharmacies partnered with Noom